Columbus, OH (April 26, 2016) – Biosortia Pharmaceuticals has launched three new oncology research projects. The projects will investigate Biosortia’s unique libraries of consortia microbial compounds for potential drug discovery in pediatric cancer (neuroblastoma), liver cancer (Hepatitis C virus), and an alternative approach to combat tumor growth by stimulating a patient’s immune responses (immuno-oncology).